09. Dec. 2011: The final allocation of the shares offered in the rights issue [...]

NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

The final allocation of the shares offered in the rights issue and the conversion issue in NorDiag ASA (the "Company") has taken place today in accordance with the allocation criteria set out in the prospectus dated 17 November 2011.

A total of 192,084,481 new shares have been allocated in the rights issue. 175,655,518 new shares were allocated to subscribers in the rights issue, and 16,428,963 new shares were allocated in accordance with the underwriting agreement entered into with existing shareholders and new investors in relation to the rights issue.  176,802,865 shares in the rights issue were allocated at a price of NOK 0.08 per share. 15,281,616 shares in the rights issue were allocated at a price of NOK 0.056 per share to the underwriters that were allocated more shares than their pro rata shareholding per 10 October 2011 implies, and where such shares were allocated by exercising of the underwriting agreement, not based on subscriptions. Through the rights issue, the Company will receive gross proceeds of approximately NOK 15 million.
 
In the conversion issue, a total of 19,193,094 new shares were allocated, whereof 10,288,985 new shares were allocated to underwriters as set off against the underwriting fee, and 8,904,109 new shares were allocated to the bridge finance lenders as set off against the interest on the bridge loan. Price per share in the conversion issue was NOK 0.056 per share. Through the conversion issue, the Company will receive gross proceeds of approximately NOK 1.1 million. The proceeds will be received by the Company through set-off against underwriting commission to the underwriters in the rights issue and interest on the bridge loan to bridge finance lenders as further described in the prospectus.
 
Notifications of allocated new shares and the corresponding subscription amount to be paid by each subscriber in the rights issue are expected to be distributed today. Payment for the allocated new shares falls due on 14 December 2011. Notifications of number of shares allocated in the conversion issue are expected to be distributed today.
 
The new shares may not be transferred or traded before they are fully paid and the share capital increase pertaining to the rights issue and the conversion issue has been registered with the Norwegian Register of Business Enterprises. It is expected that this will take place on or about 19 December 2011, immediately following which the new shares will be transferred to the VPS accounts of the subscribers and listed on Oslo Børs.
 
Following registration of the share capital increase with the Norwegian Register of Business Enterprises in connection to the rights issue and the conversion issue, the Company's share capital will be NOK 5,597,614.40, divided into 279,880,720 shares, each with a nominal value of NOK 0.02.
 
For further information, please contact:
CEO Mårten Wigstøl,   Phone: +47 911 65775
CFO Tone Kvåle,  Phone: +47 915 19576
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
For further information - www.nordiag.com.

Read the notice in Norwegian here.